Elanco buys manufacturing facility in England for $25M
Greenfield-based Elanco said the facility has played a vital role in producing a number of product lines for the firm, representing $160 million to $180 million in annual farm animal revenue.
Elanco
-
Sculpture at Elanco campus expected to make a splash for public art
“Water in Dripping, River,” a stainless steel sculpture by Chinese artist Zheng Lu, is an $846,000 project that will set a new standard for works financed through the Public Art for Neighborhoods ordinance.
Read More -
Elanco’s dermatology treatment for itchy dogs gets FDA approval
Zenrelia is one of several drugs Elanco has in its pipeline that it predicts could reach blockbuster status, which in animal health means more than $100 million in annual sales.
Read More -
IEDC still looking for buyers for portion of GM stamping plant property
Economic development leaders want the 45 acres to be developed as the OneHealth Innovation District—a partnership between Elanco Animal Health, Purdue University and the Indiana Economic Development Corp.
Read More -
Three Hancock County organizations partner to acquire Elanco’s Greenfield HQ property
Pride Investment Partners, Hancock Health and energy cooperative NineStar Connect collaborated on the purchase of the 20.4-acre site through a joint venture called HealthStar Partners.
Read More
Articles
White River State Park reveals plans for $65M expansion on stamping plant site
The park will expand into 15 acres between the White River and Elanco Animal Health’s new headquarters and will include an event pavilion to be developed inside the remnants of a former crane bay that had been part of the original stamping plant.
Elanco gets FDA approval for third new product this year
The product, called Credelio Quattro, is designed to protect against fleas, ticks, heartworms, roundworms, hookworms and three different species of tapeworms.
OneHealth designation could drive innovation in Elanco/Purdue space
State and corporate leaders believe a tech park taking shape on the western edge of downtown could be a launchpad for health sciences innovation and commercialization as part of the state’s ambitious economic development portfolio.
Elanco completes $1.3B sale of aqua business, allowing it to reduce debt load
The company had debt of $5.7 billion as of March 31 and has been under pressure from Wall Street to reduce it.
Elanco to launch product that reduces dairy cattle methane emissions
Elanco has called Bovaer a potential blockbuster, meaning it could ring up annual sales of at least $100 million.
Purdue, Elanco to develop shared-use facility at new innovation district in Indy
Elanco also announced a commitment to purchase an additional 12 acres to the north of its planned headquarters for future expansion and the development of the Epicenter for Animal Health.
Elanco reaches agreement with activist investor, avoiding messy proxy fight
The Greenfield-based maker of animal vaccines, antibiotics and other health products said that as part of the agreement with Ancora Holding Inc., it will appoint two new independent directors supported by the investment firm to its board.
Elanco digs in for fight with activist investor
Ancora Holdings Inc. is pushing for a shakeup in leadership at he Greenfield-based animal health company, which it accuses of delivering poor margins, sluggish product commercialization, negative shareholder returns and poor governance policies.
Activist investor group seeks Elanco CEO ouster, shakeup of board
Ancora Holdings Group LLC said the animal health company has underperformed its peers and destroyed billions of dollars of shareholder value.
Elanco, analysts gird for potential blockbusters in coming months
In an hourlong conference call with analysts on Monday, CEO Jeff Simmons said the word “blockbuster” at least six times as he talked about the Greenfield-based company’s pipeline products that could launch this year.
Elanco to cut 420 jobs in restructuring that will focus on pet health
The company said the restructuring is designed to shift resources from its farm animal operations to its pet health operations and help with the launch of three upcoming products now under regulatory review.
Elanco to sell aqua business to Merck for $1.3B
Elanco Animal Health said it has agreed to sell its aqua business to Merck Animal Health, a move that allows it to pay down some of its debt load and invest in new pipeline products.
Indiana business leaders form coalition to boost civic engagement
The group hopes to improve civic education in a state that ranks among the bottom nationally when it comes to voter registration and turnout.
Elanco first-quarter earnings rise to $103 million, stock climbs
The company reported earnings per share of 45 cents, handily beating Wall Street’s estimate of 29 cents. Elanco shares soared by about 9% Tuesday in premarket trading, to $9.36.
City, historians at odds over how to approach possible Black grave sites at bridge project
The Indianapolis Department of Public Works says work on the bridge will halt if remains are found during construction, and it plans to have an archaeologist on site during construction who would flag signs of burial. But critics are seeking an archeological dig first.
Elanco earns USDA’s OK for potential blockbuster parvovirus treatment
Elanco Animal Health President and CEO Jeff Simmons said the treatment is a potential blockbuster drug, with potential annual sales of more than $100 million.
Fishers-based biotech startup aims to grow from the gut
BiomEdit LLC was set up last year by Greenfield-based Elanco Animal Health and Boston-based Ginkgo Bioworks to make everything from food to therapeutics for animals. It’s already raised $36.5 million in venture capital for its work.
Pandemic pet adoptions propel rise of $500 billion global market
A wave of adoptions during the COVID-19 pandemic has created greater demand for basics like food and toys, as well as sophisticated medical care that can prolong a pet’s life.
Elanco’s shares slip to all-time low after Moody’s downgrade
Moody’s action pushed Elanco’s credit rating further into “junk bond” territory, an area considered riskier than investment-grade debt.